Press Release

Cyxone appoints Erika Samuelsson as Chief Development Officer

September 2, 2022 11:01 (CEST)

Cyxone (publ), a biotech company in autoimmune diseases, announces today that Erika Samuelsson has been appointed new Chief Development Officer (CDO) in the company as of 1 September 2022. With her broad experience from roles in project management in drug development within the biotech business, Erika will be an important part of Cyxone’s continued ambition to strengthen and develop the company.

Erika Samuelsson holds a PhD in Immunology from Lund University and has over 20 years’ experience from the Life Science field. Erika has held senior positions at Alligator Bioscience AB, Idogen AB and most recently at Immunovia AB.  She brings long experience within drug development where she has been responsible for studies in both late and early development stages. She also has extensive experience within Business Development, Alliance management and strategic communication in listed companies.

Erika will primarily be responsible for the continued non-clinical and clinical development activities, including the planned phase 2b study with Rabeximod in patients diagnosed with medium to severe rheumatoid arthritis (RA).

“I am very happy about the opportunity to contribute to the continued development of Cyxone's candidate drugs, which have the potential to improve the quality of life for a significant number of patients,” says Erika Samuelsson, CDO, Cyxone.

“We are pleased to welcome Erika to the team and with her strengthen and broaden the development competence in the company. Erika brings a lot of experience and knowledge from her previous roles that will contribute to Cyxone being able to take the next steps in the development of our two projects,” comments Carl-Magnus Högerkorp, acting CEO, Cyxone.


Carl-Magnus Högerkorp, acting CEO
Tel: +46 (0)70 781 88 12

About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit

Open press release